Multiple Sclerosis Drug Pipeline Research Report 2024: Therapeutic Assessment, Emerging Drugs, Pipeline Development Activities, Competitive Landscape [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
The assessment part of the report embraces, in depth Multiple Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Multiple Sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Multiple Sclerosis. Multiple Sclerosis Emerging Drugs Chapters This segment of the Multiple Sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery.
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic, Inc. to Participate in Investor Conference in December [Yahoo! Finance]Yahoo! Finance
- Immunic, Inc. to Participate in Investor Conference in DecemberPR Newswire
- Immunic, Inc. (NASDAQ: IMUX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Insider Buys Additional US$100k In Immunic Stock [Yahoo! Finance]Yahoo! Finance
- 75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight [Yahoo! Finance]Yahoo! Finance
IMUX
Earnings
- 11/7/24 - Miss
IMUX
Analyst Actions
- 11/25/24 - HC Wainwright
IMUX
Sec Filings
- 12/18/24 - Form 8-K
- 12/9/24 - Form 4/A
- 12/6/24 - Form 4
- IMUX's page on the SEC website